Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Does the DRD2-Taq1 A polymorphism influence treatment response to bupropion hydrochloride for reduction of the nicotine withdrawal syndrome?

Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco - 1 Dec 2003

David Sean P, Niaura Raymond, Papandonatos George D, Shadel William G, Burkholder Gary J, Britt Dana M, Day Amy, Stumpff Jeffrey, Hutchison Kent, Murphy Michael, Johnstone Elaine, Griffiths Siân-Elin, Walton Robert T

Abstract excerpt

Bupropion hydrochloride is effective in promoting long-term abstinence from smoking and may reduce risk for relapse through attenuation of withdrawal symptoms and craving. Bupropion is a weak dopamine reuptake inhibitor, and individual genetic variation in the dopamine D2 receptor has been associated with nicotine dependence in case-control studies. Thirty smokers were randomly assigned to bupropion or placebo...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Bupropion
Share to Dopamine Uptake Inhibitors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Double-Blind Method

Share to Nicotine

Share to Placebos

Share to Receptors, Dopamine D2

Share to Smoking Cessation

Share to Substance Withdrawal Syndrome

Source

Identifiers

PMID: 14668077
DOI: 10.1080/14622200310001615295

Genes

DRD2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Does the DRD2-Taq1 A polymorphism influence treatment response to bupropion hydrochloride for reduction of the nicotine withdrawal syndrome?PMID 14668077Read ↗

Bupropion efficacy for smoking cessation is influenced by the DRD2 Taq1A polymorphism: analysis of pooled data from two clinical trials.Semantic proximity Read ↗

Dopamine receptor DRD2 genotype and smoking cessation outcome following treatment with bupropion SR.Semantic proximity Read ↗

Role of functional genetic variation in the dopamine D2 receptor (DRD2) in response to bupropion and nicotine replacement therapy for tobacco dependence: results of two randomized clinical trials.Semantic proximity Read ↗

Pharmacogenetic clinical trial of sustained-release bupropion for smoking cessationSemantic proximity Read ↗

Effect of genetic polymorphisms on smoking cessation: a trial of bupropion in Korean male smokers.Semantic proximity Read ↗

Smoking Cessation Pharmacogenetics: Analysis of Varenicline and Bupropion in Placebo-Controlled Clinical TrialsSemantic proximity Read ↗

Pharmacotherapy and pharmacogenetics of nicotine dependence.Semantic proximity Read ↗

Pharmacogenetics and nicotine addiction treatment.Semantic proximity Read ↗

Dopamine D4 receptor gene variation moderates the efficacy of bupropion for smoking cessation.Semantic proximity Read ↗

Association between the DRD2 A1 allele and response to methadone and buprenorphine maintenance treatments.Semantic proximity Read ↗

Prospective association of dopamine-related polymorphisms with smoking cessation in general care.Semantic proximity Read ↗

A cost-effectiveness analysis of genetic testing of the DRD2 Taq1A polymorphism to aid treatment choice for smoking cessation.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.